
Patient Preference Studies: Regulatory Expectations and Best Practices in Study Design
Examine how regulatory and HTA expectations for patient preference studies are evolving in 2026 and what these changes mean for study design.
Home > Education Hub > Articles

Examine how regulatory and HTA expectations for patient preference studies are evolving in 2026 and what these changes mean for study design.

Discover how patient preference studies use qualitative and quantitative methods to generate decision-Grade Evidence across development and commercialization.

Discover FDA programs in 2026 that foster rare disease drug development, offering guidance, funding, and regulatory support for innovators.

Discover how a strategically planned clinical evidence generation strategy can support global device approval, maximize evidence value, and prepare for international expansion.

Explore how patient-reported outcome complexity, subtype-stratified trials, and AI are shaping product development in myasthenia gravis.

Learn how pharma and medtech convergence is reshaping drug delivery system partner selection, from combination products and regulatory readiness to integrated execution.